Citations to this article

Protection against Plasmodium falciparum malaria by PfSPZ Vaccine
Judith E. Epstein, … , B. Kim Lee Sim, Stephen L. Hoffman
Judith E. Epstein, … , B. Kim Lee Sim, Stephen L. Hoffman
Published January 12, 2017
Citation Information: JCI Insight. 2017;2(1):e89154. https://doi.org/10.1172/jci.insight.89154.
View: Text | PDF
Clinical Research and Public Health Clinical trials Vaccines

Protection against Plasmodium falciparum malaria by PfSPZ Vaccine

Abstract

BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously. The next step was to assess protective efficacy against heterologous Pf (different from Pf in the vaccine), after fewer doses, and at 24 weeks.

METHODS: The trial assessed tolerability, safety, immunogenicity, and protective efficacy of direct venous inoculation (DVI) of 3 or 5 doses of PfSPZ Vaccine in non-immune subjects.

RESULTS: Three weeks after final immunization, 5 doses of 2.7 × 105 PfSPZ protected 12 of 13 recipients (92.3% [95% CI: 48.0, 99.8]) against homologous CHMI and 4 of 5 (80.0% [10.4, 99.5]) against heterologous CHMI; 3 doses of 4.5 × 105 PfSPZ protected 13 of 15 (86.7% [35.9, 98.3]) against homologous CHMI. Twenty-four weeks after final immunization, the 5-dose regimen protected 7 of 10 (70.0% [17.3, 93.3]) against homologous and 1 of 10 (10.0% [–35.8, 45.6]) against heterologous CHMI; the 3-dose regimen protected 8 of 14 (57.1% [21.5, 76.6]) against homologous CHMI. All 22 controls developed Pf parasitemia. PfSPZ Vaccine was well tolerated, safe, and easy to administer. No antibody or T cell responses correlated with protection.

CONCLUSIONS: We have demonstrated for the first time to our knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects. A 3-dose regimen protected against both 3-week and 24-week homologous CHMI (87% and 57%, respectively) in this population. These results provide a foundation for developing an optimized immunization regimen for preventing malaria.

TRIAL REGISTRATION: ClinicalTrials.gov NCT02215707.

FUNDING: Support was provided through the US Army Medical Research and Development Command, Military Infectious Diseases Research Program, and the Naval Medical Research Center’s Advanced Medical Development Program.

Authors

Judith E. Epstein, Kristopher M. Paolino, Thomas L. Richie, Martha Sedegah, Alexandra Singer, Adam J. Ruben, Sumana Chakravarty, April Stafford, Richard C. Ruck, Abraham G. Eappen, Tao Li, Peter F. Billingsley, Anita Manoj, Joana C. Silva, Kara Moser, Robin Nielsen, Donna Tosh, Susan Cicatelli, Harini Ganeshan, Jessica Case, Debbie Padilla, Silas Davidson, Lindsey Garver, Elizabeth Saverino, Tooba Murshedkar, Anusha Gunasekera, Patrick S. Twomey, Sharina Reyes, James E. Moon, Eric R. James, Natasha KC, Minglin Li, Esteban Abot, Arnel Belmonte, Kevin Hauns, Maria Belmonte, Jun Huang, Carlos Vasquez, Shon Remich, Mary Carrington, Yonas Abebe, Amy Tillman, Bradley Hickey, Jason Regules, Eileen Villasante, B. Kim Lee Sim, Stephen L. Hoffman

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 Total
Citations: 5 14 17 23 22 17 15 16 17 146
Citation information

Citations to this article in year 2022 (23)

Title and authors Publication Year
Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults
S Jongo, L Church, V Nchama, A Hamad, R Chuquiyauri, K Kassim, T Athuman, A Deal, K Natasha, A Mtoro, M Mpina, E Nyakarungu, G Bidjimi, M Owono, E Maye, M Mangue, G Okomo, B Pasialo, D Mandumbi, M Mikue, F Mochomuemue, M Obono, J Besaha, J Bijeri, G Abegue, Y Veri, I Bela, F Chochi, J Sánchez, V Pencelli, G Gayozo, J Nlang, T Schindler, E James, Y Abebe, L Lemiale, T Stabler, T Murshedkar, M Chen, C Schwabe, J Ratsirarson, M Rivas, M Ayekaba, D Milang, C Falla, W Phiri, G García, C Maas, B Nlavo, M Tanner, P Billingsley, B Sim, C Daubenberger, S Hoffman, S Abdulla, T Richie 		The American journal of tropical medicine and hygiene 2022
Monoclonal antibodies for malaria prevention
M Aleshnick, M Florez-Cuadros, T Martinson, B Wilder 		Molecular Therapy 2022
Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies
B Wilder, V Vigdorovich, S Carbonetti, N Minkah, N Hertoghs, A Raappana, H Cardamone, B Oliver, O Trakhimets, S Kumar, N Dambrauskas, S Arredondo, N Camargo, A Seilie, S Murphy, S Kappe, D Sather 		npj Vaccines 2022
Systems analysis of immune responses to attenuated P. falciparum malaria sporozoite vaccination reveals excessive inflammatory signatures correlating with impaired immunity
Y Du, N Hertoghs, F Duffy, J Carnes, S McDermott, M Neal, K Schwedhelm, M McElrath, S Rosa, J Aitchison, K Stuart, P Jagannathan 		PLoS pathogens 2022
A First for Human Vaccinology: GMP Compliant Radiation Attenuation of Plasmodium falciparum Sporozoites for Production of a Vaccine Against Malaria
E James, S Matheny, J Overby, B Sim, A Eappen, T Li, M Li, T Richie, S Chakravarty, A Gunasekera, T Murshedkar, P Billingsley, S Hoffman 		Frontiers in immunology 2022
Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea
M Mpina, T Stabler, T Schindler, J Raso, A Deal, L Pupu, E Nyakarungu, M del Carmen Ovono Davis, V Urbano, A Mtoro, A Hamad, M Lopez, B Pasialo, M Eyang, M Rivas, C Falla, G García, J Momo, R Chuquiyauri, E Saverino, L Church, B lee Sim, B Manguire, M Tanner, C Maas, S Abdulla, P Billingsley, S Hoffman, S Jongo, T Richie, C Daubenberger 		Malaria Journal 2022
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial
M Sissoko, S Healy, A Katile, I Zaidi, Z Hu, B Kamate, Y Samake, K Sissoko, A Mwakingwe-Omari, J Lane, A Imeru, R Mohan, I Thera, C Guindo, A Dolo, K Niare, F Koïta, A Niangaly, K Rausch, A Zeguime, M Guindo, A Bah, Y Abebe, E James, A Manoj, T Murshedkar, N KC, B Sim, P Billingsley, T Richie, S Hoffman, O Doumbo, P Duffy 		The Lancet Infectious Diseases 2022
CHARM: COVID-19 Health Action Response for Marines–Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test
M Sedegah, C Porter, M Hollingdale, H Ganeshan, J Huang, C Goforth, M Belmonte, A Belmonte, D Weir, R Lizewski, S Lizewski, S Sealfon, V Jani, Y Cheng, S Inoue, R Velasco, E Villasante, P Sun, A Letizia, J Bhattacharya 		PloS one 2022
Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination
F Watson, M Shears, J Matsubara, A Kalata, A Seilie, I Talavera, T Olsen, M Tsuji, S Chakravarty, B Sim, S Hoffman, S Murphy 		The American journal of tropical medicine and hygiene 2022
Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa
J Silva, A Dwivedi, K Moser, M Sissoko, J Epstein, S Healy, K Lyke, B Mordmüller, P Kremsner, P Duffy, T Murshedkar, B Sim, T Richie, S Hoffman 		Nature Communications 2022
Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens
Ibanez J, Fendel R, Lorenz FR, Granados-Bayon P, Brückner S, Esen M, Sulyok M, Sulyok Z, Borrmann S, Bacher P, Scheffold A, Hoffman SL, Kremsner PG, Mordmüller B 		npj Vaccines 2022
Malaria-Antigene in der Ära der mRNA-Impfstoffe: Mögliche Rettungen vor einer der relevantesten und gefährlichsten Kinderkrankheiten des Globalen Südens
Borkens Y 		Monatsschrift Kinderheilkunde 2022
GMZ2 Vaccine-Induced Antibody Responses, Naturally Acquired Immunity and the Incidence of Malaria in Burkinabe Children.
Dassah S, Adu B, Tiendrebeogo RW, Singh SK, Arthur FKN, Sirima SB, Theisen M 		Frontiers in immunology 2022
A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection.
Mordmüller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, Bayon PG, Esen M, Gmeiner M, Held J, Heimann HL, Woldearegai TG, Ibáñez J, Flügge J, Fendel R, Kreidenweiss A, Kc N, Murshedkar T, Chakravarty S, Riyahi P, Billingsley PF, Church LWP, Richie TL, Sim BKL, Hoffman SL, Kremsner PG 		npj Vaccines 2022
Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children.
Feng G, Kurtovic L, Agius PA, Aitken EH, Sacarlal J, Wines BD, Hogarth PM, Rogerson SJ, Fowkes FJI, Dobaño C, Beeson JG 		BMC Medicine 2022
Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites
Chakravarty S, Shears MJ, James ER, Rai U, KC N, Conteh S, Lambert LE, Duffy PE, Murphy SC, Hoffman SL 		Malaria Journal 2022
Five decades of clinical assessment of whole-sporozoite malaria vaccines
Nunes-Cabaço H, Moita D, Prudêncio M 		Frontiers in immunology 2022
Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy
KC N, Church LW, Riyahi P, Chakravarty S, Seder RA, Epstein JE, Lyke KE, Mordmüller B, Kremsner PG, Sissoko MS, Healy S, Duffy PE, Jongo SA, Nchama VU, Abdulla S, Mpina M, Sirima SB, Laurens MB, Steinhardt LC, Oneko M, Li M, Murshedkar T, Billingsley PF, Sim BK, Richie TL, Hoffman SL 		Frontiers in immunology 2022
Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs.
Chughlay MF, Chalon S, El Gaaloul M, Gobeau N, Möhrle JJ, Berghmans PJ, Van Leuven K, Marx MW, Rosanas-Urgell A, Flynn J, Escoffier E, Izquierdo-Juncàs D, Jansen B, Mitov V, Kümmel A, Van Geertruyden JP, Barnes KI 		The American journal of tropical medicine and hygiene 2022
A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria.
Sirima SB, Ouédraogo A, Tiono AB, Kaboré JM, Bougouma EC, Ouattara MS, Kargougou D, Diarra A, Henry N, Ouédraogo IN, Billingsley PF, Manoj A, Abebe Y, Kc N, Ruben A, Richie TL, James ER, Joshi S, Shrestha B, Strauss K, Lyke KE, Plowe CV, Potter GE, Cox C, Jones W, Sim BKL, Hoffman SL, Laurens MB 		Science Translational Medicine 2022
A genetically-engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection
Murphy SC, Vaughan AM, Kublin JG, Fishbauger M, Seilie AM, Cruz KP, Mankowski T, Firat M, Magee S, Betz W, Kain H, Camargo N, Haile MT, Armstrong J, Fritzen E, Hertoghs N, Kumar S, Sather DN, Pinder LF, Deye GA, Galbiati S, Geber C, Butts J, Jackson LA, Kappe SH 		Science Translational Medicine 2022
Current approaches to malaria vaccines
Duffy PE 		Current Opinion in Microbiology 2022
Controlled Human Malaria Infection Studies in Africa—Past, Present, and Future
Kibwana E, Kapulu M, Bejon P 		Current topics in microbiology and immunology 2022

Advertisement